Prevention and treatment of thrombotic complications in pregnant, parturient and puerperal women


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Timely and adequate prescription of anticoagulants in obstetrics is a multidisciplinary area with intensive development. Prevention and treatment of thrombotic complications in pregnant, parturient and puerperal women are discussed from the standpoint of the choice of drugs, dosage regimen, the possibility of drug replacement and identification of patients in various clinical situations. Currently, low-molecular-weight heparins are the drug of choice for the prevention and treatment of venous thrombotic complications during pregnancy and the postpartum period.

Full Text

Restricted Access

About the authors

Natalia A. Gabitova

Academy of Postgraduate Education, Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency

Email: gabitova_nataliya@mail.ru
Dr. Sci. (Med.), Professor at the Department of Obstetrics and Gynecology

References

  1. Canobbio M.M., Warnes C.A., Aboulhosn J., et al. Management of Pregnancy in Patients With Complex Congenital Heart Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2017;135(8):e50-e87. Doi: 10.1161/ CIR.0000000000000458
  2. Worldatlas. Countries with the oldest average mother's age at first birth. https://www. worldatlas. com/articles/countries-with-the-highest-mother-s-mean-age-atfirst-birth.html (25 April 2017).
  3. Khan K.S., Wojdyla D, Say L, Gulmezoglu A.M., Van Look P.F. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367:1066-74. doi: 10.1016/S0140-6736(06)68397-9.
  4. Elkayam U, Goland S., Pieper FIG., Silverside C.K High-risk cardiac disease in pregnancy: Part i. J Am Coll Cardiol. 2016;68:396-410. Doi: 10.1016/j. jacc.2016.05.048.
  5. Ormesher L, Simcox L.E., Tower C, Greer Т.А. «To test or not to test», the arguments for and against thrombophilia testing in obstetrics. Obstet Med. 2017;10(2):61-6. doi: 10.1177/1753495X17695696.
  6. Rodger M.A., Gris J.C., De Vries J.I.P, et al. Low-Molecular-Weight Heparin for Placenta-Mediated Pregnancy Complications Study Group. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomized controlled trials. Lancet. 2016;388(10060):2629-41. Doi: 10.1016/ S0140-6736(16)31139-4.
  7. Croles F.N., Nasserinejad K, Duvekot J.J., et al. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis. BMJ. 2017;359:j4452. doi: 10.1136/bmj.j4452.
  8. Simcox L.E., Ormesher L, Tower C, Greer I.A. Thrombophilia and Pregnancy Complications. International journal of molecular sciences. 2015;16(12):28418-28. Published online 2015 Nov30. doi: 10.3390/ijms161226104.
  9. De Swiet M. Maternal mortality: Confidential inquiries into maternal deaths in United Kingdom. Am J Obstet Gynecol. 2000;183:1271. doi: 10.1016/s0002-9378(00)70324-3.
  10. Gerhardt A, Scharf R.E., Greer I.A, Zotz R.B. Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium. Blood. 2016;128(19):2343-49. doi: 10.1182/blood- 2016-03-703728.
  11. Leffert L, Butwick A, Carvalho B, et al. Members of the SOAP VTE Taskforce. The Society for Obstetric Anesthesia and Perinatology Consensus Statement on the Anesthetic Management of Pregnant and Postpartum Women Receiving Thromboprophylaxis or Higher Dose Anticoagulants. Anesth Analg. 2018;126(3):928-44. Doi: 10.1213/ ANE.0000000000002530.
  12. Galambosi P.J., Gissler M., Kaaja R.J. V-Matti Ulander Incidence and risk factors of venous thromboembolism during postpartum period: a population-based cohort-study. Nordic Federation of Societies of Obstetrics and Gynecology, Acta Obstetricia et Gynecologica Scandinavica. 2017;96:852-61
  13. Анестезия и интенсивная терапия пациенток, получающих антикоагулянты для профилактики и лечения венозных тромбоэмболических осложнений в акушерстве. Клинические рекомендации. Протоколы лечения. М. Письмо Минздрава РФ от 06.12.2018 № 15-4/1-/2-7862
  14. Sultan A.A., Tata L.J., West J., et al. Risk factors for first venous thromboembolism around pregnancy: Apopulation-based cohort study from the United Kingdom. Blood 2013;121:3953-61. doi: 10.1182/blood-2012-11-469551.
  15. Roeters van Lennep J.E., Meijer E., Klumper F.J., et al. Prophylaxis with low-dose low-molecular-weight heparin during pregnancy and postpartum: Is it effective? J Thromb Haemost. 2011;9:473 80. doi: 10.1111/j.1538-7836.2011.04186.x
  16. Greer I.A, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy. Blood. 2005;106:401-7. doi: 10.1182/blood-200502-0626.
  17. Van Hagen I.M., Roos-Hesselink J.W., Ruys T.P, et al. Pregnancy in women with a mechanical heart valve: Data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation. 2015;132:132-42. Doi: W.1161/CIRCUiATIONAHA.115.015242.
  18. Xu Z, Fan J., iuo X., et al. Anticoagulation regimens during pregnancy in patients with mechanical heart valves: A systematic review and meta-analysis. Can J Cardiol. 2016;32:1248.e1-1248.9. doi: 10.1016/j.cjca.2015.11.005.
  19. D'Souza R., Ostro J., Shah P.S., et al. Anticoagulation for pregnant women with mechanical heart valves: A systematic review and meta-analysis. Eur Heart J. 2017;214:S351-S351. doi: 10.1093/eurheartj/ ehx032.
  20. Bates S.M., Middeldorp S., Rodger M., et al. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41:92-128. doi: 10.1007/s11239-015-1309-0.
  21. iinkins i.A., Dans A.i., Moores i.K., et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e495S-e530S. doi: 10.1378/chest.11-2303.
  22. RCOG. Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management. Green-top Guideline No 37b. Royal College of Obstetricians and Gynaecologists; 2015.
  23. ESC Guidelines for the management of cardiovascular diseases during pregnancy European Heart J. 2018;00:1-83. Doi: 10.1093/ eurheartj/ehy340.
  24. Профилактика венозных тромбоэмболических осложнений в акушерстве и гинекологии. Клинические рекомендации (протоколы лечения). М. Письмо Минздрава РФ от 27.05.2014. № 15-4/10/2-3792. [Prevention of venous thromboembolic complications in obstetrics and gynecology Clinical recommendations (treatment protocols). M. ietter of the Ministry of health of the Russian Federation dated 27.05.2014. № 15-4/10/2-3792. (In Russ)].
  25. Stephenson M.i., Serra A.E., Neeper J.M., et al. A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. J Perinatol. 2016;36:95-9. doi: 10.1038/jp.2015.130.
  26. Overcash R.T., Somers A.T., iaCoursiere D.Y Enoxaparin dosing after cesarean delivery in morbidly obese women. Obstet Gynecol. 2015;125:1371-76. Doi: 10.1097/ AOG.0000000000000873.
  27. Goland S., Schwartzenberg S., Fan J., et al. Monitoring of anti-Xa in pregnant patients with mechanical prosthetic valves receiving lowmolecular-weight heparin: Peak or trough levels?JCardiovascPharmacol Ther. 2014;19:451-56. doi: 10.1177/1074248414524302.
  28. Knight M. UKOSS. Antenatal pulmonary embolism: Risk factors, management and outcomes. BJOG. 2008;115:453-61. doi: 10.1111/j.1471-0528.2007.01622.x.
  29. Friedrich E., Hameed A.B. Fluctuations in antifactor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy. J Perinatol. 2010;30:253-57. doi: 10.1038/jp.2009.164.
  30. Ormesher i., Simcox i., Tower C., Greer I.A. Management of inherited thrombophilia in pregnancy. Womens Health (iond). 2016;12(4):41-433. doi: 10.1177/1745505716653702.
  31. ieffert i., Butwick A., Carvalho B., et al.; members of the SOAP VTE Taskforce. The Society for Obstetric Anesthesia and Perinatology Consensus Statement on the Anesthetic Management of Pregnant and Postpartum Women Receiving Thromboprophylaxis or Higher Dose Anticoagulants. Anesth Analg. 2018;126(3):928-44. Doi: 10.1213/ ANE.0000000000002530.
  32. Sauter T.C., Eberle B., Wuillemin W.A.,., et al. How I manage patients with anticoagulation-associated bleeding or urgent surgery. Swiss Med. Wkly. 2018;14:wl4598. Doi: 10.4414/ smw.2018.14598.
  33. van Veen J.J., Maclean R.M., Hampton K.K., et al. Protamine reversal of low molecular weight heparin: Clinically effective? Blood Coagul Fibrinolysis. 2011;22:565-70. Doi: 10.1097/ MBC.0b013e3283494b3c.
  34. van Aart i., Eijkhout H.W., Kamphuis J.S., et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: An open, prospective randomized controlled trial. Thromb Res. 2006;118:313-20. doi: 10.1016/j.thromres.2005.08.005.
  35. Chai-Adisaksopha C., Hillis C., Siegal D.M., et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost. 2016;116:879-90. doi: 10.1160/TH16-04-0266.
  36. Cauldwell M., Steer PJ., Swan i., et al. The management of the third stage of labour in women with heart disease. Heart. 2017;103:945-51. doi: 10.1136/heartjnl-2016-310607.
  37. James A.H., Jamison M.G., Brancazio L.R., Myers E.R. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194:1311-15. Doi: 10.1016/j. ajog.2005.11.008.
  38. Pomp E.R., Ienselink A.M., RosendaalF.R., Doggen C.J. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6:632-37. doi: 10.1111/j.1538-7836.2008.02921.x.
  39. iouis S.G., Sato M., Geraci T., et al. Correlation of Missed Doses of Enoxaparin With Increased Incidence of Deep Vein Thrombosis in Trauma and General Surgery Patients. JAMA Surg. 2014;149(4):365-70. Doi: 10.1001/ jamasurg.2013.3963.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies